Editing Inverse agonist (section)

=== G protein-coupled receptor inverse agonists ===
<!--Endogenous examples-->
Two known endogenous inverse agonists are the [[Agouti-related peptide]] (AgRP) and its associated peptide [[Agouti signalling peptide]] (ASIP). AgRP and ASIP appear naturally in humans and bind [[melanocortin receptors]] 4 and 1 ([[melanocortin 4 receptor|Mc4R]] and [[melanocortin 1 receptor|Mc1R]]), respectively, with nanomolar affinities.<ref name="pmid9450927">{{cite journal|vauthors=Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS|date=February 1998|title=Interaction of Agouti protein with the melanocortin 1 receptor in vitro and in vivo|journal=Genes & Development|volume=12|issue=3|pages=316–30|doi=10.1101/gad.12.3.316|pmc=316484|pmid=9450927}}</ref>

<!--Exogenous examples-->
The [[opioid antagonist]]s [[naloxone]] and [[naltrexone]] act as [[Receptor antagonist|neutral antagonists]] of the [[mu opioid receptors]] under basal conditions, but as inverse agonists when an opioid such as [[morphine]] is bound to the same channel. 6α-naltrexo, [[6β-Naltrexol|6β-naltrexol]], 6β-naloxol, and 6β-naltrexamine acted [[Receptor antagonist|neutral antagonists]] regardless of opioid binding and caused significantly reduced withdrawal jumping when compared to [[naloxone]] and [[naltrexone]].<ref name="pmid11413242">{{cite journal|vauthors=Wang OD, Raehal KM, Bilsky EJ, Sadée W|date=June 2001|title=Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence |journal= Journal of Neurochemistry|volume=77|issue=3|pages=1590–600|doi=10.1046/j.1471-4159.2001.00362.x|pmid=11413242|s2cid=10026688 |doi-access=free}}</ref>

Nearly all antihistamines acting at [[H1 receptors]] and [[H2 receptors]] have been shown to be inverse agonists.<ref name=":0">{{cite journal| pmc=3195115 | pmid=22021988 | doi=10.4103/0253-7613.84947 | volume=43 | issue=5 | title=Inverse agonism and its therapeutic significance | year=2011 | journal=Indian J Pharmacol | pages=492–501 | author=Khilnani G, Khilnani AK | doi-access=free }}</ref>

The [[beta blockers]] [[carvedilol]] and [[bucindolol]] have been shown to be low level inverse agonists at [[beta adrenoceptors]].<ref name=":0" />